NCT | Study type | Participants | Conditions | Circulating markers | Phase | Aims | Reference |
NCT03695601 | Observational, prospective | 1600 | Heart transplant rejection | dd-cfDNA | N/A | To monitor heart transplant recipients for allograft rejection. | 115 |
NCT01020916 | Interventional, randomised | 950 | Out-of-hospital cardiac arrest | miRNA-124-3p | N/A | To evaluate a target temperature management after cardiac arrest. | 116 |
NCT02299960 | Observational, prospective | 101 | Heart failure, hypertension, pulmonary hypertension, diabetic nephropathies | CECs | N/A, completed | To correlate analyse test–retest reliability (EndoPAT), circulating endothelial cells and and endothelial function in CV patients. | 20 |
NCT00699998 | Interventional, randomised | 9326 | Acute coronary syndrome | miRNAs | Phase III, completed | To assess the efficacy and safety of novel combination therapy and useful biomarkers. | 62 |
NCT02325765 | Observational, retrospective | 100 | Congential cardiac surgery | Histones | Completed | To determine the correlation between circulating histones and the development of SIRS. | 68 |
NCT02194686 | Interventional, randomised | 71 | CV diseases | EPCs | Phase IV, completed | To evaluate the effects of cilostazol on human early EPCs and endothelial function. | 117 |
NCT01096875 | Interventional, randomised | 60 | Coronary artery bypass surgery, elective surgical procedure | EPCs | Phase IV, completed | To test if atorvastatin augments the number of EPCs after cardiopulmonary bypass. | 118 |
CECs, circulating endothelial cells; CV, cardiovascular; dd-cfDNA, donor-derived cell-free DNA; EPCs, endothelial progenitor cells;miRNA, micro-RNAs; N/A, not applicable; SIRS, systemic inflammatory response syndrome.